Alector, Inc. (ALEC) SEC Filings & Earnings Calls

Dilution risk from large equity offering

“36.6M shares issued at $2.05, representing significant dilution.”

Cash burn concern

“Company raising $75M via equity, suggesting insufficient cash from operations.”

Underwater options and repricing signal potential talent retention risk and depressed stock price.

“majority of stock options held by Company employees were 'underwater'... repricing to $1.87 per share.”

Dependence on Genentech for development and commercialization of AL050

“Genentech will be responsible for development, regulatory, manufacturing, and commercialization across all indications” · word for word

Milestone payments contingent on future success

“additional payments of up to $1.17 billion upon the achievement of development, regulatory, and commercial milestones” · word for word

Pre-revenue biotech with significant clinical and regulatory risk; AL137 IND still pending.

“No approved products; pipeline entirely preclinical/early clinical; cash runway through 2027 but no revenue.”

Competition in Alzheimer's space from approved anti-amyloid therapies (e.g., Leqembi, donanemab).

“AL137 is an anti-amyloid beta antibody, competing with established therapies.”

Collaboration Termination Risk

“On July 6, 2026, GSK provided written notice to the Company terminating the GSK Agreement” · word for word

Clinical Trial Failure Risk

“In April 2026, GSK discontinued the global Phase 2 PROGRESS-AD trial of nivisnebart ... following a pre-specified interim futility analysis” · word for word

Cash Runway Risk

“Net cash used in operating activities was $84.0 million for the six months ended June 30, 2026”

Clinical trial failure and partnership termination create existential risk for a pre-revenue biotech.

“Phase 3 INFRONT-3 failed; Phase 2 PROGRESS-AD discontinued; GSK terminated collaboration.”

Cash burn without revenue or partnership support increases financing risk.

“Loan repayment of $10.4M; no new funding sources disclosed.”

Dilution risk from potential equity issuance up to $125M, which may pressure stock price.

“Company may offer and sell up to $125,000,000 of shares of common stock”

Clinical Trial Failure

“In April 2026, GSK discontinued the global Phase 2 PROGRESS-AD trial of nivisnebart” · word for word

Pipeline Dependency

“This next generation pipeline, built on the ABC platform and distinct from our prior clinical programs, positions us to develop therapeutic candidates for a range of neurodegenerative diseases.” · word for word

Financing Risk

“We will need to obtain substantial additional funding in the future for our research and development activities and continuing operations.” · word for word

Pre-revenue biotech with clinical-stage pipeline; no approved products; cash burn risk.

“No revenue reported; pipeline in preclinical/IND-enabling stages.”

Clinical trial risk; PROGRESS-AD interim futility analysis in 1H 2026 could be negative.

“Independent interim futility analysis for PROGRESS-AD Phase 2 trial expected in first half of 2026.”

Collaboration revenue decline; dependency on partnership with GSK.

“Collaboration revenue declined significantly due to satisfaction of performance obligations.”

Clinical Trial Failure

“Latozinemab failed to meet the clinical co-primary endpoint in that trial.” · word for word

Capital Requirement

“We will need to obtain substantial additional financing to complete the development and any commercialization of our product candidates.” · word for word

No Approved Products

“We have no products approved for commercial sale and have not generated any revenue from product sales.” · word for word

Debt Covenant Restrictions

“The Loan Agreement contains customary representations and warranties, events of default and affirmative and negative covenants, including covenants that limit or restrict our ability to, among other things, dispose of assets, enter into certain licensing arrangements, effect certain mergers, incur debt, grant liens, pay dividends or other distributions on ou” · word for word

Phase 3 clinical trial failure

“Latozinemab did not meet the clinical co-primary endpoint of slowing FTD-GRN progression.” · word for word

Workforce reduction execution risk

“On October 21, 2025, the Company committed to a plan to reduce its workforce by approximately 47%.” · word for word

Dependence on GSK collaboration

“Collaboration revenue decreased to $3.3 million for the three months ended September 30, 2025 from $15.3 million for the same period in 2024.”

Clinical trial failure risk materialized with latozinemab Phase 3 miss

“INFRONT-3 Phase 3 clinical trial of latozinemab did not demonstrate clinical benefit; open-label extension discontinued.” · word for word

Workforce reduction may impact operational capacity and morale

“Reduction in force of approximately 47% implemented in October 2025.”